Axsome Therapeutics, Inc.
AXSM
$121.91
$0.260.21%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 24.06% | -3.86% | -18.13% | -509.35% | -61.09% |
| Total Depreciation and Amortization | 19.14% | 18.24% | 18.00% | 10.17% | 2.84% |
| Total Amortization of Deferred Charges | 55.95% | 7.18% | -29.48% | 5.99% | 31.21% |
| Total Other Non-Cash Items | -47.14% | 150.68% | 5.65% | 50.63% | 319.42% |
| Change in Net Operating Assets | 273.69% | 156.09% | 272.97% | 29.29% | -79.49% |
| Cash from Operations | 13.70% | 65.21% | 45.60% | -818.52% | -10.15% |
| Capital Expenditure | -328.57% | 75.74% | 60.90% | -38.03% | 96.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -328.57% | 75.74% | 60.90% | -38.03% | 96.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,434.24% | -12.28% | -92.22% | 546.25% | -59.53% |
| Repurchase of Common Stock | -90.36% | -33.24% | -298.80% | -86.62% | -71.78% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -183.74% | 49.29% | 86.06% | 35.47% | 45.81% |
| Cash from Financing | 712,300.00% | -8.89% | -94.16% | -102.30% | -100.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.53% | 156.86% | -108.28% | -219.88% | -13.84% |
